Market open
Nektar Therapeutics/NKTR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Ticker
NKTR
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
137
Website
NKTR Metrics
BasicAdvanced
$250M
Market cap
-
P/E ratio
-$0.90
EPS
0.67
Beta
-
Dividend rate
Price and volume
Market cap
$250M
Beta
0.67
52-week high
$1.93
52-week low
$0.41
Average daily volume
957K
Financial strength
Current ratio
5.149
Quick ratio
4.782
Long term debt to equity
248.807
Total debt to equity
275.582
Interest coverage (TTM)
-5.34%
Management effectiveness
Return on assets (TTM)
-20.16%
Return on equity (TTM)
-128.02%
Valuation
Price to revenue (TTM)
2.865
Price to book
3.56
Price to tangible book (TTM)
3.14
Price to free cash flow (TTM)
-1.522
Growth
Revenue change (TTM)
6.17%
Earnings per share change (TTM)
-44.63%
3-year revenue growth (CAGR)
-4.05%
3-year earnings per share growth (CAGR)
-29.94%
What the Analysts think about NKTR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Nektar Therapeutics stock.
NKTR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
NKTR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Nektar Therapeutics stock?
Nektar Therapeutics (NKTR) has a market cap of $250M as of October 14, 2024.
What is the P/E ratio for Nektar Therapeutics stock?
The price to earnings (P/E) ratio for Nektar Therapeutics (NKTR) stock is 0 as of October 14, 2024.
Does Nektar Therapeutics stock pay dividends?
No, Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders as of October 14, 2024.
When is the next Nektar Therapeutics dividend payment date?
Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders.
What is the beta indicator for Nektar Therapeutics?
Nektar Therapeutics (NKTR) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.